First Horizon Advisors’s Exagen XGN Stock Holding History

First Horizon Advisors’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,378	Closed	-$3K	–	2542
2022 Q3	$3K	Buy	1,378 +85	+7%	+$474	﹤0.01%	1937
2022 Q2	$7K	Buy	1,293 +798	+161%	+$4.65K	﹤0.01%	1729
2022 Q1	$4K	Sell	495 -719	-59%	-$6.2K	﹤0.01%	1357
2021 Q4	$14K	Hold	1,214	–	–	﹤0.01%	1428
2021 Q3	$17K	Buy	+1,214	New	+$16.1K	﹤0.01%	1344

Other funds holding XGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

First Horizon Advisors's XGN Position: Q4 2022 in Review

First Horizon Advisors sold out of Exagen (XGN) in Q4 2022, closing a stake of 1,378 shares — an estimated $3K sold.

First Horizon Advisors first reported a position in XGN in Q3 2021 and held it in 5 quarters. The position peaked at $17K in Q3 2021. 31 funds tracked by Wall St. Rank hold XGN as of Q4 2022.

First Horizon Advisors reported no remaining Exagen position as of Q4 2022 after selling out during the quarter.
First Horizon Advisors sold 1,378 Exagen shares in Q4 2022, an estimated $3K.
First Horizon Advisors first reported a position in Exagen in Q3 2021 and held it in 5 quarters.
First Horizon Advisors's Exagen position peaked at $17K in Q3 2021.
31 funds tracked by Wall St. Rank held Exagen as of Q4 2022.

Based on First Horizon Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.